Table 1.
Results of laboratory measurements.
| Before treatment | After treatment | |
|---|---|---|
| CD31 | + | |
| CD34 | + | |
| ERG | + | |
| Ki67 | 50.00% (+) | |
| S100 | – | |
| CK | – | |
| WBC (/L) | 5.78 × 109 | 5.55 × 109 |
| RBC (/L) | 4.55 × 1012 | 4.87 × 1012 |
| Hb (g/L) | 140.00 | 146.00 |
| PLT (/L) | 177.00 × 109 | 183.00 × 109 |
| Occult blood | Negative | |
| C-Reactive protein | Negative | |
| Total bilirubin (µmol/L) | 20.07 | |
| Direct bilirubin (µmol/L) | 6.90 (0 - 6.8) | |
| Indirect bilirubin (µmol/L) | 13.17 | |
| Total protein (g/L) | 67.00 | |
| Albumin (g/L) | 37.20 | |
| Globulin (g/L) | 29.80 | |
| A/G | 1.25 (1.25 - 2.5) | |
| Glutamic-pyruvic transaminase (U/L) | 9.20 | |
| Glutamic oxalacetic transaminase (U/L) | 14.67 | |
| Alkaline phosphatase (U/L) | 68.00 | |
| Glutamyltranspeptidase (U/L) | 90.00 | |
| Ureophil (mmo1/L) | 5.37 (2.86 - 8.20) | |
| Creatinine (µmol/L) | 105.58 (21.5 - 104) | |
| Uric Acid (µmol/L) | 403.25 (208 - 428) | |
| Prothrombin time (s) | 11.30 (9 - 14) | |
| Mobility (%) | 97.30 (70 - 150) | |
| International normalized ratio (PT) | 0.97 (0.8 - 1.5) | |
| Fibrinogen (g/L) | 4.31 (2 - 4) | |
| Activated partial thromboplastin time | 26.80 (20 - 40) | |
| Thrombin time (s) | 16.00 (14 - 21) | |
| D-Dimer (mg/L) | 1.77 (0 - 0.55) |